Halder Venture Approves Auditor Changes, Capital Increase, and Warrant Issue
Halder Venture's board approved the resignation of its internal auditor and appointed M/s J Kumar Jain & Associates. The company will increase its authorized share capital from ₹13.42 crore to ₹18.42 crore. Additionally, it approved the issuance of 7,93,650 convertible warrants at ₹315 each to specified persons, including P.K. Bio Link Private Limited for ₹24.99 crore. Shareholder approval is required for capital increase and warrant issuance.
The approval for increasing authorized share capital and issuing convertible warrants represents a significant corporate action that could impact the company's capital structure and future equity dilution. The appointment of a new auditor is a standard procedural change. These actions, especially the warrant issuance, have the potential to influence investor perception and future funding.
The announcement details routine corporate actions such as auditor changes and capital structure adjustments, along with a warrant issuance. While the warrant issuance could be viewed positively for fundraising, the overall impact is considered neutral as it requires shareholder approval and is part of ongoing corporate governance.
Halder Venture Limited announced key decisions made during its Board Meeting held on March 26, 2026. The Board accepted the resignation of the company's Internal Auditor, M/s Somnath Ray & Associates, effective March 18, 2026, due to preoccupation.
Subsequently, M/s J Kumar Jain & Associates, a Kolkata-based chartered accountant firm established in 2018, was appointed as the new Internal Auditor for the Financial Year 2025-2026. The firm is peer-reviewed and offers a range of auditing, tax consultancy, and assurance services.
The Board also approved an increase in the company's authorized share capital from ₹13.42 crore to ₹18.42 crore, by creating an additional 50,00,000 equity shares of ₹10 each. This change to the Memorandum of Association is subject to shareholder approval via postal ballot.
Furthermore, the company received approval to create, issue, and offer up to 7,93,650 convertible warrants, each with a face value of ₹10 and an issue price of ₹315 (including a premium of ₹305). These warrants are convertible into one fully paid-up equity share and will be issued to specified persons/entities, including P.K. Bio Link Private Limited, which is proposed to be allotted 7,93,650 warrants for ₹24.99 crore. This issuance is also subject to shareholder approval through postal ballot. The company also approved the notice for the postal ballot to seek shareholder consent.
What to do with a filing like this
Halder Venture Limited filed this with the NSE as a statutory disclosure, categorised under auditor changes. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Halder Venture Limited. Read the original for the full detail.